Cargando…
The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GL...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733138/ https://www.ncbi.nlm.nih.gov/pubmed/26597956 http://dx.doi.org/10.1007/s11096-015-0219-8 |
_version_ | 1782412799280939008 |
---|---|
author | de Boer, Stefanie Amarens Lefrandt, Joop Daniel Petersen, Japke Frida Boersma, Hendrikus Hessel Mulder, Douwe Johannes Hoogenberg, Klaas |
author_facet | de Boer, Stefanie Amarens Lefrandt, Joop Daniel Petersen, Japke Frida Boersma, Hendrikus Hessel Mulder, Douwe Johannes Hoogenberg, Klaas |
author_sort | de Boer, Stefanie Amarens |
collection | PubMed |
description | Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74) to 60 (52–67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56–150) to 60 (0–100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (−3.1 %) and restrained (n = 41) in the greatest (−10.3 %) in comparison with emotional (n = 37, −8.5 %) and indifferent (n = 25, −9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11096-015-0219-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4733138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-47331382016-02-05 The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour de Boer, Stefanie Amarens Lefrandt, Joop Daniel Petersen, Japke Frida Boersma, Hendrikus Hessel Mulder, Douwe Johannes Hoogenberg, Klaas Int J Clin Pharm Research Article Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74) to 60 (52–67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56–150) to 60 (0–100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (−3.1 %) and restrained (n = 41) in the greatest (−10.3 %) in comparison with emotional (n = 37, −8.5 %) and indifferent (n = 25, −9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11096-015-0219-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-11-23 2016 /pmc/articles/PMC4733138/ /pubmed/26597956 http://dx.doi.org/10.1007/s11096-015-0219-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Article de Boer, Stefanie Amarens Lefrandt, Joop Daniel Petersen, Japke Frida Boersma, Hendrikus Hessel Mulder, Douwe Johannes Hoogenberg, Klaas The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title_full | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title_fullStr | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title_full_unstemmed | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title_short | The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
title_sort | effects of glp-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733138/ https://www.ncbi.nlm.nih.gov/pubmed/26597956 http://dx.doi.org/10.1007/s11096-015-0219-8 |
work_keys_str_mv | AT deboerstefanieamarens theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT lefrandtjoopdaniel theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT petersenjapkefrida theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT boersmahendrikushessel theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT mulderdouwejohannes theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT hoogenbergklaas theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT deboerstefanieamarens effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT lefrandtjoopdaniel effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT petersenjapkefrida effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT boersmahendrikushessel effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT mulderdouwejohannes effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour AT hoogenbergklaas effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour |